Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Stanford University
National Institutes of Health Clinical Center (CC)
PMV Pharmaceuticals, Inc
Mayo Clinic
Kivu Bioscience Inc.
ViroMissile, Inc.
Pfizer
Pfizer
Pfizer
Tizona Therapeutics, Inc
Aulos Bioscience, Inc.
ALX Oncology Inc.
Clasp Therapeutics, Inc.
University of California, San Diego
BioNTech SE
OHSU Knight Cancer Institute
Eli Lilly and Company
MacroGenics
Adaptimmune
University of California, San Diego
Solve Therapeutics
Eli Lilly and Company
National Cancer Institute, Egypt
Kidney Cancer Research Bureau
Second Life Therapeutics
Onchilles Pharma Inc
Ocellaris Pharma, Inc.
University Health Network, Toronto
University of Pittsburgh
M.D. Anderson Cancer Center
Hoffmann-La Roche
OncoNano Medicine, Inc.
GlaxoSmithKline
Regeneron Pharmaceuticals
VM Oncology, LLC
Takeda
Memorial Sloan Kettering Cancer Center
University of Chicago
AccSalus Biosciences, Inc.
Therorna
Tempus AI
M.D. Anderson Cancer Center
Incyte Corporation
M.D. Anderson Cancer Center
Sanofi
Sichuan Baili Pharmaceutical Co., Ltd.
BioAtla, Inc.
Sun Yat-sen University
GI Innovation, Inc.